MindBio Phase 2 LSD-Microdosing Clinical Trial In Patients With Major Depressive Disorder Begins Pre-Screening Participants
Portfolio Pulse from Vuk Zdinjak
MindBio Therapeutics Corp. has begun pre-screening participants for its phase 2 LSD-microdosing clinical trials. The trials will assess the treatment's effectiveness in patients with major depressive disorder over an 8-week period. Previous trials have shown positive results, including improved sleep quality and significant enhancements in feelings of wellness, creativity, happiness, social connectivity, and energy.
July 19, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindBio Therapeutics is moving forward with phase 2 clinical trials for its LSD-microdosing treatment. Positive results from previous trials could indicate potential success, which may positively impact the company's stock.
The progression to phase 2 clinical trials indicates that MindBio's LSD-microdosing treatment has shown promise in earlier stages. If the phase 2 trials also yield positive results, this could increase investor confidence in the company and potentially drive up the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100